

**Publikationen aus dem Labor translationale Forschung, Stand September 2024**

1. Engel, J., Wieder, V., Bauer, M., Kaufhold, S., Stückrath, K., Wilke, J., Hanf, V., Uleer, C., Lantsch, T., Peschel, S., John, J., Pöhler, M., Weigert, E., Bürrig, K.-F., Buchmann, J., Santos, P., Kantelhardt, E.J., Thomssen, C., Vetter, M., 2024. Prognostic and predictive impact of NOTCH1 in early breast cancer. *Breast Cancer Res Treat.* <https://doi.org/10.1007/s10549-024-07444-1>
2. Bauer, M., Vetter, M., Stückrath, K., Yohannes, M., Desalegn, Z., Yalew, T., Bekuretsion, Y., Kenea, T.W., Joffe, M., van den Berg, E.J., Nikulu, J.I., Bakarou, K., Manraj, S.S., Ogunbiyi, O.J., Ekanem, I.-O., Igbinoba, F., Diomande, M., Adebamowo, C., Dzamalala, C.P., Anele, A.A., Zietsman, A., Galukande, M., Foerster, M., dos-Santos-Silva, I., Liu, B., Santos, P., Jemal, A., Abebe, T., Wickenhauser, C., Seliger, B., McCormack, V., Kantelhardt, E.J., 2023. Regional Variation in the Tumor Microenvironment, Immune Escape and Prognostic Factors in Breast Cancer in Sub-Saharan Africa. *Cancer immunology research* 11, 720–731. <https://doi.org/10.1158/2326-6066.CIR-22-0795>
3. Desalegn, Z., Smith, A., Yohannes, M., Cao, X., Anberber, E., Bekuretsion, Y., Assefa, M., Bauer, M., Vetter, M., Kantelhardt, E.J., Abebe, T., Starlard-Davenport, A., 2023. Human Breast Tissue Microbiota Reveals Unique Microbial Signatures that Correlate with Prognostic Features in Adult Ethiopian Women with Breast Cancer. *Cancers* 15. <https://doi.org/10.3390/cancers15194893>
4. Thomssen, C., Vetter, M., Kantelhardt, E.J., Meisner, C., Schmidt, M., Martin, P.M., Clatot, F., Augustin, D., Hanf, V., Paepke, D., Meinerz, W., Hoffmann, G., Wiest, W., Sweep, F.C.G.J., Schmitt, M., Jänicke, F., Loibl, S., Minckwitz, G. von, Harbeck, N., 2023. Adjuvant Docetaxel in Node-Negative Breast Cancer Patients: A Randomized Trial of AGO-Breast Study Group, German Breast Group, and EORTC-Pathobiology Group. *Cancers* 15. <https://doi.org/10.3390/cancers15051580>
5. Bachmann, H.S., Jung, D., Link, T., Arnold, A., Kantelhardt, E., Thomssen, C., Wimberger, P., Vetter, M., Kuhlmann, J.D., 2022. FNTB Promoter Polymorphisms Are Independent Predictors of Survival in Patients with Triple Negative Breast Cancer. *Cancers* 14. <https://doi.org/10.3390/cancers14030468>
6. Desalegn, Z., Yohannes, M., Porsch, M., Stückrath, K., Anberber, E., Santos, P., Bauer, M., Addissie, A., Bekuretsion, Y., Assefa, M., Worku, Y., Taylor, L., Abebe, T., Kantelhardt, E.J., Vetter, M., 2022. Intrinsic subtypes in Ethiopian breast cancer patient. *Breast cancer research and treatment* 196, 495–504. <https://doi.org/10.1007/s10549-022-06769-z>
7. Erber, R., Angeloni, M., Stöhr, R., Lux, M.P., Ulbrich-Gebauer, D., Pelz, E., Bankfalvi, A., Schmid, K.W., Walter, R.F.H., Vetter, M., Thomssen, C., Mayr, D., Klauschen, F., Sinn, P., Sotlar, K., Stering, K., Stenzinger, A., Wunderle, M., Fasching, P.A., Beckmann, M.W., Hoffmann, O., Kimmig, R., Harbeck, N., Wuerstlein, R., Ferrazzi, F., Hartmann, A., 2022. Molecular Subtyping of Invasive Breast Cancer Using a PAM50-Based Multigene Expression Test-Comparison with Molecular-Like Subtyping by Tumor Grade/Immunohistochemistry and Influence on Oncologist's Decision on Systemic Therapy in a Real-World Setting. *International journal of molecular sciences* 23. <https://doi.org/10.3390/ijms23158716>
8. Reinhardt, K., Stückrath, K., Hartung, C., Kaufhold, S., Uleer, C., Hanf, V., Lantsch, T., Peschel, S., John, J., Pöhler, M., Bauer, M., Bürrig, F.K., Weigert, E., Buchmann, J., Kantelhardt, E.J., Thomssen, C., Vetter, M., 2022. PIK3CA-mutations in breast cancer. *Breast cancer research and treatment* 196, 483–493. <https://doi.org/10.1007/s10549-022-06637-w>

9. Schüler, K., Bethmann, D., Kaufhold, S., Hartung, C., Stückrath, K., Lantsch, T., Uleer, C., Hanf, V., Peschel, S., John, J., Pöhler, M., Buchmann, J., Bürrig, K.-F., Weigert, E., Thomssen, C., Kantelhardt, E.J., Vetter, M., 2022. Prognostic Value of Tumour-Infiltrating Lymphocytes in an Unselected Cohort of Breast Cancer Patients. *Diagnostics (Basel, Switzerland)* 12.  
<https://doi.org/10.3390/diagnostics12102527>
10. Berdiel-Acer, M., Maia, A., Hristova, Z., Borgoni, S., Vetter, M., Burmester, S., Becki, C., Michels, B., Abnaof, K., Binenbaum, I., Bethmann, D., Chatziioannou, A., Hasmann, M., Thomssen, C., Espinet, E., Wiemann, S., 2021. Stromal NRG1 in luminal breast cancer defines pro-fibrotic and migratory cancer-associated fibroblasts. *Oncogene* 40, 2651–2666.  
<https://doi.org/10.1038/s41388-021-01719-3>
11. Bley, N., Schott, A., Müller, S., Misiak, D., Lederer, M., Fuchs, T., Aßmann, C., Glaß, M., Ihling, C., Sinz, A., Pazaitis, N., Wickenhauser, C., Vetter, M., Ungurs, O., Strauss, H.-G., Thomssen, C., Hüttelmaier, S., 2021. IGF2BP1 is a targetable SRC/MAPK-dependent driver of invasive growth in ovarian cancer. *RNA biology* 18, 391–403. <https://doi.org/10.1080/15476286.2020.1812894>.
12. Hartung, C., Porsch, M., Stückrath, K., Kaufhold, S., Staege, M.S., Hanf, V., Lantsch, T., Uleer, C., Peschel, S., John, J., Pöhler, M., Weigert, E., Buchmann, J., Bürrig, K.-F., Schüler, K., Bethmann, D., Große, I., Kantelhardt, E.J., Thomssen, C., Vetter, M., 2021. Identifying High-Risk Triple-Negative Breast Cancer Patients by Molecular Subtyping. *Breast care (Basel, Switzerland)* 16, 637–647.  
<https://doi.org/10.1159/000519255>
13. Mitra, D., Vega-Rubin-de-Celis, S., Royla, N., Bernhardt, S., Wilhelm, H., Tarade, N., Poschet, G., Buettner, M., Binenbaum, I., Borgoni, S., Vetter, M., Kantelhardt, E.J., Thomssen, C., Chatziioannou, A., Hell, R., Kempa, S., Müller-Decker, K., Wiemann, S., 2021. Abrogating GPT2 in triple-negative breast cancer inhibits tumor growth and promotes autophagy. *International journal of cancer* 148, 1993–2009. <https://doi.org/10.1002/ijc.33456>.
14. Reibold, C.F., Tariku, W., Eber-Schulz, P., Getachew, S., Addisie, A., Unverzagt, S., Wienke, A., Hauptmann, S., Wickenhauser, C., Vetter, M., Jemal, A., Thomssen, C., Kantelhardt, E.J., 2021. Adherence to Newly Implemented Tamoxifen Therapy for Breast Cancer Patients in Rural Western Ethiopia. *Breast care (Basel, Switzerland)* 16, 484–490. <https://doi.org/10.1159/000512840>.
15. Bauer, M., Kantelhardt, E.J., Stiewe, T., Nist, A., Mernberger, M., Politt, K., Hanf, V., Lantsch, T., Uleer, C., Peschel, S., John, J., Buchmann, J., Weigert, E., Bürrig, K.-F., Wickenhauser, C., Thomssen, C., Bartel, F., Vetter, M., 2019. Specific allelic variants of SNPs in the MDM2 and MDMX genes are associated with earlier tumor onset and progression in Caucasian breast cancer patients. *Oncotarget* 10, 1975–1992. <https://doi.org/10.18632/oncotarget.26768>
16. Bley, N., Schott, A., Müller, S., Misiak, D., Lederer, M., Fuchs, T., Aßmann, C., Glaß, M., Ihling, C., Sinz, A., Pazaitis, N., Wickenhauser, C., Vetter, M., Ungurs, O., Strauss, H.-G., Thomssen, C., Hüttelmaier, S., 2021. IGF2BP1 is a targetable SRC/MAPK-dependent driver of invasive growth in ovarian cancer. *RNA biology* 18, 391–403. <https://doi.org/10.1080/15476286.2020.1812894>
17. Hartung, C., Porsch, M., Stückrath, K., Kaufhold, S., Staege, M.S., Hanf, V., Lantsch, T., Uleer, C., Peschel, S., John, J., Pöhler, M., Weigert, E., Buchmann, J., Bürrig, K.-F., Schüler, K., Bethmann, D., Große, I., Kantelhardt, E.J., Thomssen, C., Vetter, M., 2021. Identifying High-Risk Triple-Negative Breast Cancer Patients by Molecular Subtyping. *Breast care (Basel, Switzerland)* 16, 637–647.  
<https://doi.org/10.1159/000519255>

18. Mitra, D., Vega-Rubin-de-Celis, S., Royla, N., Bernhardt, S., Wilhelm, H., Tarade, N., Poschet, G., Buettner, M., Binenbaum, I., Borgoni, S., Vetter, M., Kantelhardt, E.J., Thomssen, C., Chatziioannou, A., Hell, R., Kempa, S., Müller-Decker, K., Wiemann, S., 2021. Abrogating GPT2 in triple-negative breast cancer inhibits tumor growth and promotes autophagy. *International journal of cancer* 148, 1993–2009. <https://doi.org/10.1002/ijc.33456>
19. Reibold, C.F., Tariku, W., Eber-Schulz, P., Getachew, S., Addisie, A., Unverzagt, S., Wienke, A., Hauptmann, S., Wickenhauser, C., Vetter, M., Jemal, A., Thomssen, C., Kantelhardt, E.J., 2021. Adherence to Newly Implemented Tamoxifen Therapy for Breast Cancer Patients in Rural Western Ethiopia. *Breast care (Basel, Switzerland)* 16, 484–490. <https://doi.org/10.1159/000512840>
20. Bauer, M., Kantelhardt, E.J., Stiewe, T., Nist, A., Mernberger, M., Politt, K., Hanf, V., Lantzsch, T., Uleer, C., Peschel, S., John, J., Buchmann, J., Weigert, E., Bürrig, K.-F., Wickenhauser, C., Thomssen, C., Bartel, F., Vetter, M., 2019. Specific allelic variants of SNPs in the MDM2 and MDMX genes are associated with earlier tumor onset and progression in Caucasian breast cancer patients. *Oncotarget* 10, 1975–1992. <https://doi.org/10.18632/oncotarget.26768>
21. Berchtold, E., Vetter, M., Gündert, M., Csaba, G., Fathke, C., Ulbrich, S.E., Thomssen, C., Zimmer, R., Kantelhardt, E.J., 2019. Comparison of six breast cancer classifiers using qPCR. *Bioinformatics (Oxford, England)* 35, 3412–3420. <https://doi.org/10.1093/bioinformatics/btz103>
22. Kuhlmann, J.D., Bachmann, H.S., Link, T., Wimberger, P., Kröber, E., Thomssen, C., Mallé, B., Bethmann, D., Vetter, M., Kantelhardt, E.J., 2019. Association of caspase 8 polymorphisms -652 6N InsDel and Asp302His with progression-free survival and tumor infiltrating lymphocytes in early breast cancer. *Scientific reports* 9, 12594. <https://doi.org/10.1038/s41598-019-47601-x>

**Buchbeitrag:**

1. Kantelhardt EJ, Vetter M, Strauß H-G: Mammakarzinomrezidiv und metastasiertes Mammakarzinom; in Wacker J, Sillem M, Bastert G, Beckmann MW (eds): *Therapiehandbuch Gynäkologie und Geburtshilfe*, 3. Auflage. Berlin, Heidelberg, Springer, 2020, pp 421–437.

**Herausgeberschaft:**

1. *Tumorbiologie und Diagnostik des primären Mammakarzinoms*, Hsgb. Martina Vetter, Eva Kantelhardt, UNI-MED SIENCE, Bremen, 2015, ISBN 978-3-8374-1492-9